Saratov JOURNAL of Medical and Scientific Research

Tactical approaches to management of patients with macular pathology

Year: 2020, volume 16 Issue: №2 Pages: 683-687
Heading: Ophtalmology Article type: Original article
Authors: Chuprov A.D., Borshchuk E.L., Voronina A.E., Lositskiy А.О.
Organization: S. Fyodorov Eye Microsurgery Federal State Institution

The purpose is to evaluate the effectiveness of tactical approaches to macular pathology treatment based on retrospective data analysis. Material and Methods. Between 2014 and 2019, 12007 courses of treatment of patients with macular pathology (1372 patients) were conducted at the S. Fyodorov Eye Microsurgery Federal State Institution, Orenburg branch. 69.5% of patients were diagnosed with "Macular and posterior pole degeneration" (H35.3), "Retinal angiomatosis" (H35.0) was diagnosed in 11.3%, cases with "Other specified retinal disorders" (H35.8) 9.4%. Results. Comparison of the best corrected visual acuity (BCVA) was made and 2 groups were distinguished: group 1 consisted of patients with negative dynamics, group 2 included patients with positive dynamics. Among all patients, the best values of BCVA were in patients diagnosed with "Other specified retinal disorders", while BCVA improved by 0.13 in most patients with this nosology, in case of macular edema (1.8% of the sample), an improvement in BCVA by 0.13 was also noted. Tactical approaches were analyzed in patients with the best BCVA values, and it was found that intravitreal injection of drugs (IVID) more often led to an increase or stabilization of BCVA in patients with various pathologies of the macular zone. In the sample the majority of patients with macular pathology were diagnosed with "Macular and posterior pole degeneration", 65.35% of patients in this nosological group had positive dynamics in BCVA in the course of 3 years. Conclusion. The most effective method of treating patients with the diagnosis "Macular and posterior pole degeneration" was intravitreal injection of angiogenesis inhibitors (Aflibercept and Ranibizumab) according to the regimen described in the instructions for these drugs.

1. Birch DG, Liang FQ. Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomedicine 2007; 2 (1): 65-77. DOI: 10.2147/nano. 2007.2.1.65.
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2014; 2 (2): e106-e116. DOI: 10.1016/S2214-109X(13) 70145-13.
3. Neroev VV. Visual impairment in the Russian Federation: Report at the ophthalmological congress "White Nights — 2017", St. Petersburg. URL: (30 April 2020).
4. Neroev VV. Russia's nationwide epidemiological noninvasive study of patients with wet age-related macular degeneration. Russian Ophthalmological Journal 2011; 4 (2): 4-9.
5. Bikbov MM, Fayzrakhmanov RR, Yarmukhametova AL. Age-related macular degeneration. Moscow: Aprel, 2013; 196 p.
6. Fayzrakhmanov RR, Arslangareeva II, Gilmanshin TR, Fatkhutdinov AKh. Features of structuralometric changes in post-occlusive macular edema. Ophthalmology: Eastern Europe 2015: 66-7.
7. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc of the National Academy of Sciences 2002; 99 (17): 11393-8. DOI: 10.1073/pnas. 172398299.
8. Borshchuk EL, Voronina AE. Comparative assessment of quality of life criteria in patients with ophthalmopathology. Bulletin of Orenburg State University 2014; 173 (12): 73-9.
9. Bobykin EV Modes of application of antiangiogenic therapy for the treatment of macular diseases in ophthalmology: Literature review. Practical Medicine 2018; 16 (5): 104-11.
10. Schmidt-Erfurth U, Kaiser РК, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121 (1): 193-201. DOI: 10.1016/j. ophtha. 2013.08.011.

2020_02-1_683-687.pdf338.78 KB

No votes yet